

# NAS: DEFINITION, DIAGNOSIS AND CODING

**Greg A. Barretto, Jr., MD, MS**  
Regional Medical Director | Director of Outreach  
Division of Newborn Medicine

**Carol Gilmour, MD, MPH**  
Clinical Assistant Professor of Pediatrics  
Division of Newborn Medicine

**Gysella Muniz, MD**  
Regional Director of Quality Newborn Care  
Director of Children's Newborn Nursery Service

UPMC Magee Womens Hospital | UPMC Children's Hospital of Pittsburgh

# Objectives

- Review the definition, diagnosis and assessment of Neonatal Abstinence Syndrome (NAS)
- Understand the importance of having a standard case definition of NAS.
- Reflect on how your institution defines NAS.
- Identify and understand the different ICD-10-CM codes for NAS.

# Neonatal Abstinence Syndrome (NAS)

- withdrawal in a newborn shortly after birth from in utero exposure to opioids or non-opioid substances
  - nicotine, antidepressants (SSRIs), benzodiazepines, stimulants (amphetamines, cocaine), opioids (methadone, buprenorphine, morphine, oxycodone, heroin)
- result of the sudden discontinuation of fetal exposure to substances that were used by the mother during pregnancy
- more recently called Neonatal Opioid Withdrawal Syndrome (NOWS) if prenatal exposure is limited to opioids

# NAS: DIAGNOSIS

- Clinical diagnosis is based:
  - history (or suspected history) of maternal opioid use disorder
  - positive maternal or infant urine toxicology screening for opioids
  - clinical findings that are consistent with NOWS
- NOT defined or diagnosed by the need for pharmacotherapy but by the cardinal signs of withdrawal.

# NOWS: Clinical Presentation

- Sleep and wake cycle disturbances
  - fragmented sleep with short sleep cycles
  - difficulty maintaining an alert state
- Alterations in tone or movement
  - hypertonicity
  - tremors
  - jitteriness


# NOWS: Clinical Presentation

- Autonomic dysfunction
  - sweating
  - sneezing
  - mottling
  - fever or unstable temperature
  - nasal stuffiness
  - yawning

# NOWS: Clinical Presentation

- Easy overstimulation, sensitivity, or hyperarousal resulting in irritability and crying with any stimuli, or rarely seizures
- Difficulties with feeding (suck-swallow incoordination and oral hypersensitivities) resulting in poor weight gain, tachypnea, gassiness, vomiting, and loose stools

# NAS: Clinical Presentation



# NAS: How do we approach it?

- Maternal Care
- Neonatal Assessment
  - Modified Finnegan scoring tool
  - Eat Sleep Console: Scoring tool + standardized non-pharma care interventions
- Neonatal Therapy
  - Non-Pharmacologic approach
  - Pharmacologic approach



# NAS: Assessment

- assessment of an infant at risk for NAS centers on their ability to eat, sleep and be consoled
- can be achieved either through:
  - Modified Finnegan Scoring Tool
  - Eat, Sleep, Console Tool (ESC)



# Modified Finnegan Scoring Tool

Central Nervous System Disturbances	Metabolic, Vasomotor, and Respiratory Disturbance	Gastrointestinal Disturbance
Excessive High Pitched Crying – 2 Continuous High Pitched Crying - 3	Sweating – 1	Excessive Sucking – 1
Sleep < 1 Hr After Feeding – 3 Sleep < 2 Hr After Feeding – 2 Sleep < 3 Hr After Feeding – 1	Fever < 101 (37.2 – 38.3 C) – 1 Fever > 101 (38.4 C) – 2	Poor feeding – 2
Hyperactive Moro Reflex – 2 Markedly Hyperactive Moro – 3	Frequent Yawning (>3) – 1	Regurgitation – 2 Projective Vomiting – 3
Mild Tremors Disturbed – 1 Mod – Severe Tremors Disturbed – 2	Mottling – 1	Loose Stools – 2 Watery Stools – 3
Mild Tremors Undisturbed – 3 Mod – Sev Tremors Undisturbed - 4	Nasal Stuffiness – 1	
Increased Muscle Tone - 2	Sneezing (>3) – 1	
Excoriation – 1	Nasal Flaring – 2	
Myoclonic Jerk – 3	Respiratory Rate (>60) – 1 Respiratory Rate (>60 w Retractions) – 2	
Seizures – 5		

# Modified Finnegan Scoring Tool

- The score of 8 appears to be derived from the following quote from Finnegan's original 1975 article:
  - *"The infant with a score of 7 or less was not treated with drugs for the abstinence syndrome because, in our experience, he would recover rapidly with swaddling and demand feedings. Infants whose score was 8 or above were treated pharmacologically."*<sup>1</sup>
- The score of 8 was chosen from 1 institution's experience and has been adopted by most institutions nationwide.<sup>2</sup>

1. Finnegan LP, Connaughton JF Jr., Kron RE, Emich JP. Neonatal abstinence syndrome: assessment and management. *Addict Dis.* 1975;2(1-2):141-158

2. Mehta A, Forbes KD, Kuppala VS. Neonatal abstinence syndrome management from prenatal counseling to postdischarge follow-up care: results of a national survey. *Hosp Pediatr.* 2013;3(4):317-323

# What is Eat, Sleep, Console?


- Novel, noninvasive, safe approach to assess infants with NAS
- Focused on infant's ability to function regardless of the withdrawal symptoms.
- Mother and Non-Pharm care = FIRST LINE TREATMENT
- Originally established by Grossman et al. at (Yale NHCH)
- Northern New England PQIN (New Hampshire, Vermont, Maine)
- Neonatal Quality Improvement Collaborative of Massachusetts (neoQIC)



# ESC Assessments

- Every 3-4 hours (at times of feedings/cares)
- Encompass the last 3-4 hours since the prior assessment
- Feedback from all caregivers
- Does not require the infant to be removed from the mother to complete





<b>Poor eating due to NAS? Yes / No</b>				
<b>SLEEPING</b>				
<b>Sleep &lt; 1 hr due to NAS? Yes / No</b>				
<b>CONSOLING</b>				
<b>Unable to console within 10 min due to NAS? Yes / No</b>				
<b>Soothing support used to console infant:</b>				
Soothes with little support: 1				
Soothes with some support: 2				
Soothes with much support or does not soothe in 10 min: 3				
<b>PARENTAL / CAREGIVER PRESENCE</b>				
<b>Parental / caregiver presence since last assessment:</b>				
No parent present: 0				
1 - 59 minutes: 1				
1 hr - 1 hr 59 min: 2				
2 hr - 2 hr 59 min: 3				
3 hr+: 4				
<b>MANAGEMENT DECISION</b>				
<b>Recommend a Team Huddle? Yes / No</b>				
<b>Management decision:</b>				
Optimize non-pharm care: 1				
Initiate medication treatment: 2				
Other (please describe):				
<b>NON-PHARM INTERVENTIONS</b>				
<b>Rooming-in: Increased / Reinforced</b>				
<b>Parental presence: Increased / Reinforced</b>				
<b>Skin-to-skin contact: Increased / Reinforced</b>				
<b>Holding by caregiver/cuddler: Increased / Reinforced</b>				
<b>Swaddling: Increased / Reinforced</b>				
<b>Optimal feeding: Increased / Reinforced</b>				
<b>Non-nutritive sucking: Increased / Reinforced</b>				
<b>Quiet environment: Increased / Reinforced</b>				
<b>Limit visitors: Increased / Reinforced</b>				
<b>Clustering care: Increased / Reinforced</b>				

Mode: [Accordion](#) [Expanded](#) [View All](#)

[1m](#) [5m](#) [10m](#) [15m](#) [30m](#) **[1h](#)** [2h](#) [4h](#) [8h](#) [24h](#) Based On: 0700 | [Reset](#) [Now](#)

	<b>Admission (Current...)</b>
	5/5/17
	<b>1000</b>

**Eating**

Poor feeding due to NAS  [📄](#) [🔍](#)

**Sleeping**

<1 hr after feeding due to NAS

**Consolability**

Infant's consolability rating

Unable to console within 10 minutes

Caregiver(s) providing the consolability

**Parental Presence**

Parental presence since last assessment

**Cuddler Present**

Cuddler present

**Team Huddle**

Team huddle

# DATA: HOW IT CAN MAKE US WORK HARDER, INSTEAD OF SMARTER!




# Quality Improvement... the first few minutes

- *How are we doing?*

• *How do we know?*

- *How can we do better?*

# Newborn NOWS Process Improvement



Infants ≥ 35 wk with NAS:

- Decrease hospital length of stay by 1 day by June 30, 2021.
- Decrease initiation of pharmacologic therapy by 20% by June 30, 2021.

Infants ≥ 35 wk with NAS:  
by 1 day by June 30, 2021.  
June 30, 2021.

- Decrease hospital length of stay  
by 20% by June 30, 2021.  
- Decrease initiation of pharmacologic therapy by 20% by June 30, 2021.

Improve identification and use standardize coding and documentation for substance exposed newborns and infants diagnosed with Neonatal Abstinence Syndrome (NAS)

Improve identification and use standardize coding and documentation for substance exposed newborns and infants diagnosed with Neonatal Abstinence Syndrome (NAS)

- Standardize definition of Substance Exposed Newborns (SEN)
- Standardize definition of NAS
- Standardize coding and documentation for SEN and NAS

Improve understanding of Substance use Disorder (SUD) and NAS

- Engagement with WHSL Perinatal SUD Committee (Cindy Huhn and Sharon Sabella)
- Educate staff regarding NAS
- Provide family education about NAS

Improve identification and use standardize coding and documentation for substance exposed newborns and infants diagnosed with Neonatal Abstinence Syndrome (NAS)

- Enhance existing education on the use of the modified Finnegan scoring system
- Improve reliability with

- Standardize definition of Substance Exposed Newborns (SEN)
- Standardize definition of NAS
- Standardize coding and documentation for SEN and NAS

Standardize pharmacologic management for all SEN and infants diagnosed with NAS

- Adopt and adapt the current UPMC CHP NAS Clinical Guidelines
- Explore the safe use of clonidine as secondary
- Enhance existing education on the use of pharmacologic management for staff therapy

Ensure the safe discharge of mother and baby

- Engagement with WHSL Perinatal SUD Committee (Cindy Huhn and Sharon Sabella)
- Partner with families to establish an inpatient “plan of safe care”
- Partner with families to establish an outpatient “plan of safe care”

# PA Case Management System (iCMS)

- Internet Case Management System (iCMS)
- Goal... providing a single comprehensive data system:
  - support newborn metabolic, hearing, and critical congenital heart defects (CCHD) screening follow-up programs
  - provides fast and accurate identification of infants and their newborn screening results

# PA iCMS Implementation: NAS

January 2018 – NAS becomes a reportable condition to the PA DOH

- NAS cases...
  - should be reported within 4 days of discharge or within 28 days of life, whichever comes first
  - include **confirmed and probable** cases using clinical and laboratory criteria defined in the Council of State and Territorial Epidemiologists' (CSTE) NAS Standardize Case Definition
  - It is recommended the **P96.1** be the discharge code for neonates with clinical signs of withdrawal **and** confirmed neonatal or maternal laboratory results or maternal history

# iCMS: NAS Reporting Form

## Patient Information

\* Reporting Date

\* Reporting Facility/Midwife

\* Medical Record #

Initial FP #

\* Infant's Legal Last Name

\* Infant's Legal First Name

\* Infant's DOB

\* Gender

\* Birth Order

Apgar Score 1 minute

Apgar Score 5 minutes

\* Mother's First Name

\* Mother's Last Name

\* Mother's DOB

\* Location of Infant Care (check all that apply)

Nursery  Transfer  Outpatient

NICU  Readmission

Principle Source of Payment

# iCMS: NAS Reporting Form

**Neonate Assessment Scoring (complete all that apply, at least one)**

\* Finnegan highest Score

\* Modified Finnegan highest score

\* None

\* Other

\* If Other, please specify the scoring method and the score

# iCMS: NAS Reporting Form

## Infant Status

Medications or Therapy Used to Treat Infant (check all that apply)

- Clonidine
- Methadone
- Other drug
- Chlorpromazine
- Morphine
- Nonpharmacologic therapy
- Diazepam
- Phenobarbital
- No treatment

\* Infant Signs/Symptoms of Withdrawal (check all that apply)

- Body shakes (tremors)
- Poor feeding (including poor or excessive suck)
- Loose stools
- Seizures (convulsions)
- Tachypnea
- Vomiting
- Hyperactive Moro reflex
- Fever
- Nasal congestion
- Myoclonus (including hiccups)
- Blotchy skin
- Sneezing
- Hypertonia
- Poor sleep
- Skin abrasions or excoriation
- High-pitched cry
- Lots of yawning
- Other symptoms attributed to NAS

\* If other, please specify

^  
v

# iCMS: NAS Reporting Form

## Laboratory Testing Performed

\* Was laboratory testing of neonate for substance exposure performed?

\* If yes, what was the source of the lab sample?

\* If other, please specify

\* If positive results, which drug(s) did the infant test positive for?



# iCMS: NAS Reporting Form

## Infant's Discharge Plan

\* Was a notification made to Childline?

\* Was a plan of safe care initiated?

\* If yes, Contact Name for plan of safe care:

\* If yes, Contact Phone Number for plan of safe care: ( ) -   
Extension

\* Who was the baby referred to post-discharge? (check all that apply)

Early Intervention     Pediatrician experienced in working with NAS     Developmental assessment clin  
 Home visiting services     High-risk infant follow-up clinic     Other  
 Medical home

\* If other, please specify

\* Infant discharge date

\* Who was the infant discharged to?

\* If other, please specify.

# iCMS: NAS Reporting Form

## PCP Information

Infant's PCP

Name  
Address  
City, State, Zip  
Phone #  
Fax #

PCP Name

Address 1

Address 2

City

State

Zip Code

Phone # ( ) -

Fax # ( ) -

Email



# iCMS: NAS Reporting Form

## Mother's Discharge Plan

Did the mother's discharge plan include referrals to any of the following? (check all that apply)

- Continued MAT treatment
- Parenting support
- Other behavioral health services
- Care for substance use
- Community support programs
- Other
- Home visitation services

\* If Other, please specify

# iCMS: NAS Reporting Form

## Antenatal Maternal Drug Use

Evidence of any maternal drug use in any medical record (mother or infant)?

Was the mother receiving MAT during pregnancy?

- Maternal drugs used during antenatal period (check all that apply)
- |  |  |   |
|--|--|---|
| <input type="checkbox"/> Alcohol/ethanol                     | <input type="checkbox"/> Gabapentin              | <input type="checkbox"/> Methamphetamine      |
| <input type="checkbox"/> Amphetamines                        | <input type="checkbox"/> Hallucinogens/inhalants | <input type="checkbox"/> Morphine             |
| <input type="checkbox"/> Antidepressants                     | <input type="checkbox"/> Heroin                  | <input type="checkbox"/> Naltrexone           |
| <input type="checkbox"/> Antipsychotics                      | <input type="checkbox"/> Hydrocodone             | <input type="checkbox"/> Opiates              |
| <input type="checkbox"/> Barbiturates                        | <input type="checkbox"/> Hydromorphone           | <input type="checkbox"/> Oxycodone            |
| <input type="checkbox"/> Benzodiazepines                     | <input type="checkbox"/> Hydromorphone           | <input type="checkbox"/> Phencyclidine        |
| <input type="checkbox"/> Buprenorphine (Subutex or Suboxone) | <input type="checkbox"/> Kratom                  | <input type="checkbox"/> Propoxyphene         |
| <input type="checkbox"/> Bupropion (e.g. Wellbutrin)         | <input type="checkbox"/> Marijuana/hash          | <input type="checkbox"/> Tobacco/e-cigarettes |
| <input type="checkbox"/> Cocaine                             | <input type="checkbox"/> Methadone               | <input type="checkbox"/> Tramadol             |
| <input type="checkbox"/> Codeine                             | <input type="checkbox"/> Meperidine              | <input type="checkbox"/> Other                |
| <input type="checkbox"/> Fentanyl                            |  |   |

\* If Other, please specify

Relating only to antenatal opioid use, indicate mother's treatment received during delivery and/or postpartum

- |  |                                       |                                |
|--|---------------------------------------|--------------------------------|
| <input type="checkbox"/> Methadone                           | <input type="checkbox"/> No treatment | <input type="checkbox"/> Other |
| <input type="checkbox"/> Buprenorphine (Subutex or Suboxone) | <input type="checkbox"/> Unknown      |                                |

\* If Other, please specify

# iCMS: Which cases do we report?

- **confirmed and probable cases** identified using clinical and laboratory data as defined in the Council of State and Territorial Epidemiologists' (CSTE) NAS Standardized Case Definition
- **suspect cases** are NOT reported
- **Not limited** to infants treated with pharmacologic therapy. Report infants treated with non-pharmacologic therapy that meet the definition of NAS.

# CSTE: Case Definition

Tier 1. Reporting to PA DOH based on case identification using clinical record.

CRITERION	CONFIRMED	PROBABLE	SUSPECT
<b>CLINICAL EVIDENCE</b>			
<i>Neonate</i>			
Diagnoses or Chief complaint of NAS	•		
Clinical presentation of NAS (≥ 3 signs)		•	
<i>Maternal: chronic drug use 4 weeks prior to delivery</i>			
opioid, benzodiazepines or barbiturate			
non-opioid, non-benzodiazepines or non-barbiturate			
unknown drug type			
<b>LABORATORY EVIDENCE</b>			
<i>Neonate</i>			
Positive	•	•	
Absent or Unknown			
<i>Maternal: blood or urine</i>			
Positive			
Positive: non-opioid, non-benzodiazepines or non-barbiturate			
Absent or Unknown			

# CSTE: Case Definition


Tier 2. Reporting based on administrative data (e.g. payer claims) using ICD-10-CM.

CRITERION	CONFIRMED or PROBABLE	SUSPECT		
<b>CODING OF THE NEONATE</b>				
<i>Confirmatory diagnostic coding</i>				
P96.1 NAS	●			
<i>Suspect diagnostic code</i>				
P04.14 Newborn affected by maternal use of opiates		●		
P04.17 Newborn affected by maternal use of sedatives-hypnotics			●	
P04.1A Newborn affected by maternal use of anxiolytics				●



# CSTE: Reporting Criteria?

CRITERION	NAS TIER 1: CLINICAL RECORDS	NAS TIER 2: ADMINISTRATIVE DATA
<i><u>Clinical Criteria</u></i>		
Hospitalized NEONATE (< 28 days) with clinical signs consistent with NAS.	●	
Hospitalized NEONATE whose healthcare record contains information (diagnosis, chief complaint or discharge code) about suspected NAS.	●	●
NEONATE in a residential pediatric recovery center whose healthcare record contains information about suspected NAS.	●	●
NEONATE whose healthcare record contains information about in utero exposure to opioids, benzodiazepines, or barbiturates.	●	●
<i><u>Laboratory Criteria</u></i>		
Positive NEONATAL: opioids, benzodiazepines, or barbiturates, or their metabolites.	●	
Positive MATERNAL: opioids, benzodiazepines, or barbiturates, or their metabolites in blood or urine collected up to 4 weeks prior to delivery.	●	



# CHALLENGES IN DIAGNOSTIC CODING OF NEONATAL DRUG EXPOSURE



# Purpose of DIAGNOSIS Codes


- Standardized summary of patient conditions
- Standardized for diagnosis-specific statistical analyses
  - Public health (M&M): global
  - Health services research (cost, visits/service utilization)
  - Research databases and funding
- Prediction and planning for healthcare needs
- Required to support professional and facility billing
  - Establish medical necessity of billed service(s)
  - Must be supported by documentation
- Quality metrics, Pay-for-Performance, Contracting




# ICD-10-CM CODEBOOK

## ORGANIZATION

- Chapter
- Block
- Category
- [Subcategory]
- Code



## PERINATAL GUIDELINES (13 PAGES)



# P04.1x Newborn affected by other maternal medication

- Name of category implies prescribed but no guidance given
- Includes the only specific code for opiate
  - Assumption: includes opioids
- Specific codes for
  - P04.11 Newborn affected by maternal antineoplastic chemotherapy
  - P04.12 Newborn affected by maternal cytotoxic drugs
  - P04.13 Newborn affected by maternal use of anticonvulsants
  - P04.14 Newborn affected by maternal use of opiates
  - P04.15 Newborn affected by maternal use of antidepressants
  - P04.16 Newborn affected by maternal use of amphetamines
  - P04.17 Newborn affected by maternal use of sedative-hypnotics
  - P04.1A Newborn affected by maternal use of anxiolytics
  - P04.18 Newborn affected by other maternal medication
  - P04.19 Newborn affected by maternal use of unspecified medication

Highlighted: Potential for misuse or abuse

## P04.4x Newborn affected by maternal use of drugs of addiction

- P04.40 Newborn affected by maternal use of unspecified drugs of addiction
- P04.41 Newborn affected by maternal use of cocaine
- P04.42 Newborn affected by maternal use of hallucinogens
- P04.49 Newborn affected by maternal use of other drugs of addiction

## P04.x other Newborn affected by maternal use of codes

- P04.2 Newborn affected by maternal use of tobacco
- P04.3 Newborn affected by maternal use of alcohol
- P04.5 Newborn affected by maternal use of nutritional chemical substances
- P04.6 Newborn affected by maternal exposure to environmental chemical substances
- P04.81 Newborn affected by maternal use of cannabis
- P04.89 Newborn affected by other maternal noxious substances
- P04.9 Newborn affected by maternal noxious substances, unspecified



# Neonatal withdrawal

- P96.1

Neonatal withdrawal symptoms from **maternal use of drugs of addiction**

- Does not differentiate between “withdrawal” and “discontinuation syndrome”
- Is not specific to opiates
- Does not define a severity of withdrawal signs
- Does not require pharmacologic therapy



# Which code(s)?

- What about suspected but unverified exposure?
- Should we code every (known) exposure or only when clinical signs of withdrawal?
- With poly-drug use, how do we know which drug(s) are affecting newborn condition?
- What are the costs and benefits of adding codes to chart? (to patient, facility, payor, public health, providers, research, QI)
- What's the difference between all the codes in EHR search? How do I tell which one is right?




# CODING GUIDELINES

- Code to the highest level of specificity. “Other” and “Unspecified” codes are used when a specific code does not exist.
- Select codes that describe signs, as opposed to diagnoses, when a definitive diagnosis has not been established/confirmed.
- Signs that are associated routinely with a disease process should not be assigned as additional codes (unless otherwise instructed)
- Should a condition originate in the perinatal period, and continue throughout the life of the patient, the perinatal code should continue to be used regardless of the patient’s age
  - Perinatal period is 0-28 days old (= DOL 1-29)



# Diagnostic coding for NOWS



Some select P04.49:Newborn affected by maternal use of other drugs of addiction for illicit opiate/opioid use

# Diagnostic uncertainty: NOWS, serotonin syndrome and/or other withdrawal (antidepressant discontinuation syndrome)

Clinical Sign	Opiate	SSRI/SNRI	Gabapentin	Nicotine	Caffeine
Irritability	X	X		X	X
Tremor	X			X	X
Muscular	hypertonia	hypotonia	Arch, myoclonus	hypertonia	
Poor sleep	X	X	X		
Respiratory	tachypnea	Distress, apnea	X		
GI	X	X	X		X
Poor feeding	X	X	?	X	
Poor transition		X	X		



## P04.x: “Newborn affected by maternal use of...” uncertain classification

Drug: Rx use or illicit	ICD-10-CM	ICD-10-CM description
Opiate: acute pain, chronic pain, opiate use disorder, non-prescribed		
	P04.14	Newborn affected by maternal use of opiates
	P04.49	Newborn affected by maternal use of other drugs of addiction
Gabapentin: neuropathic pain, partial seizures, treatment-resistant mood/anxiety disorder, insomnia, PTSD		
	P04.18	Newborn affected by other maternal medication
	P04.13	Newborn affected by maternal use of anticonvulsants
	P04.49	Newborn affected by maternal use of other drugs of addiction
	P04.1A	Newborn affected by maternal use of anxiolytics
Clonazepam: panic disorder, seizure, anxiety, mania, insomnia, PTSD		
	P04.17	Newborn affected by maternal use of sedative-hypnotics
	P04.1A	Newborn affected by maternal use of anxiolytics
	P04.13	Newborn affected by maternal use of anticonvulsants
	P04.18	Newborn affected by other maternal medication



# Social determinants of health

- Risk factors for adverse outcomes
- Coordination of community resources
- May increase complexity of Medical Decision Making (E/M level) and/or DRG
- Z codes: Factors Influencing Health Status and Contact with Health Services



# icd10cmtool.cdc.gov

The screenshot shows a web browser window with the URL `icd10cmtool.cdc.gov/?fy=FY2021&q=opiate`. The page header includes the CDC logo and the text "Centers for Disease Control and Prevention CDC 24/7: Saving Lives, Protecting People™". A navigation bar identifies the user as being at the "National Center for Health Statistics". The main content area is titled "ICD-10-CM" and shows the "Fiscal Year" set to "FY2021 - includes January 2021 Addenda". A search bar contains the term "opiate". To the right of the search bar are links for "Preface | Guidelines | Help Guide | Print" and "Find code in Tabular List of Diseases", along with "Enter Code" and "View" buttons. Below the search bar, a horizontal menu shows counts for different categories: "Index to Diseases and Injuries" (11), "External Causes of Injuries Index" (0), "Table of Drugs and Chemicals" (14), and "Table of Neoplasms" (0). The "Index to Diseases and Injuries" section is expanded, showing a list of codes and descriptions related to opiate use, such as "Dependence (on) (syndrome) F19.20" and "Opiate analgesic Z79.891". The "Table of Drugs and Chemicals" section is also visible, with a sub-section for "Poisoning" containing four entries: "Poisoning Accidental", "Poisoning Intentional", "Poisoning", and "Poisoning".



# icd10cmtool.cdc.gov

The screenshot shows a web browser window with the URL `icd10cmtool.cdc.gov/?fy=FY2021&q=opiate`. The page header includes the CDC logo and the text "Centers for Disease Control and Prevention" and "National Center for Health Statistics". A navigation bar at the top right says "HAVE QUESTIONS? Email [nchsicd10CM@cdc.gov](mailto:nchsicd10CM@cdc.gov)".

## Tabular List of Diseases: P04.14

Legend: [i](#) [e](#) [g](#) [G](#) [v](#) [r](#) [o](#)

CHAPTER 16: Certain conditions originating in the perinatal period (P00-P96)	<a href="#">i</a> <a href="#">e</a> <a href="#">o</a>
<b>Newborn affected by maternal factors and by complications of pregnancy, labor, and delivery (P00-P04)</b>	<a href="#">i</a> <a href="#">e</a> <a href="#">o</a>
P04 Newborn affected by noxious substances transmitted via placenta or breast milk	<a href="#">i</a> <a href="#">e</a> <a href="#">o</a>
<b>P04.0 Newborn affected by maternal anesthesia and analgesia in pregnancy, labor and delivery</b>	<a href="#">i</a> <a href="#">e</a> <a href="#">o</a>
P04.1 Newborn affected by other maternal medication	<a href="#">i</a> <a href="#">e</a> <a href="#">g</a> <a href="#">G</a> <a href="#">v</a> <a href="#">r</a> <a href="#">o</a>
<b>P04.11 Newborn affected by maternal antineoplastic chemotherapy</b>	<a href="#">i</a> <a href="#">e</a> <a href="#">g</a> <a href="#">G</a> <a href="#">v</a> <a href="#">r</a> <a href="#">o</a>
<b>P04.12 Newborn affected by maternal cytotoxic drugs</b>	<a href="#">i</a> <a href="#">e</a> <a href="#">g</a> <a href="#">G</a> <a href="#">v</a> <a href="#">r</a> <a href="#">o</a>
<b>P04.13 Newborn affected by maternal use of anticonvulsants</b>	<a href="#">i</a> <a href="#">e</a> <a href="#">g</a> <a href="#">G</a> <a href="#">v</a> <a href="#">r</a> <a href="#">o</a>
<b>P04.14 Newborn affected by maternal use of opiates</b>	<a href="#">i</a> <a href="#">e</a> <a href="#">g</a> <a href="#">G</a> <a href="#">v</a> <a href="#">r</a> <a href="#">o</a>
<b>P04.15 Newborn affected by maternal use of antidepressants</b>	<a href="#">i</a> <a href="#">e</a> <a href="#">g</a> <a href="#">G</a> <a href="#">v</a> <a href="#">r</a> <a href="#">o</a>
<b>P04.16 Newborn affected by maternal use of amphetamines</b>	<a href="#">i</a> <a href="#">e</a> <a href="#">g</a> <a href="#">G</a> <a href="#">v</a> <a href="#">r</a> <a href="#">o</a>
<b>P04.17 Newborn affected by maternal use of sedative-hypnotics</b>	<a href="#">i</a> <a href="#">e</a> <a href="#">g</a> <a href="#">G</a> <a href="#">v</a> <a href="#">r</a> <a href="#">o</a>
<b>P04.18 Newborn affected by other maternal medication</b>	<a href="#">i</a> <a href="#">e</a> <a href="#">g</a> <a href="#">G</a> <a href="#">v</a> <a href="#">r</a> <a href="#">o</a>
<b>P04.19 Newborn affected by maternal use of unspecified medication</b>	<a href="#">i</a> <a href="#">e</a> <a href="#">g</a> <a href="#">G</a> <a href="#">v</a> <a href="#">r</a> <a href="#">o</a>
<b>P04.1A Newborn affected by maternal use of anxiolytics</b>	<a href="#">i</a> <a href="#">e</a> <a href="#">g</a> <a href="#">G</a> <a href="#">v</a> <a href="#">r</a> <a href="#">o</a>
P04.2 Newborn affected by maternal use of tobacco	<a href="#">i</a> <a href="#">e</a> <a href="#">o</a>
P04.3 Newborn affected by maternal use of alcohol	<a href="#">i</a> <a href="#">e</a> <a href="#">o</a>



# icd10cmtool.cdc.gov

The screenshot shows a web browser window with the URL `icd10cmtool.cdc.gov/?fy=FY2021&q=opiate`. The page header includes the CDC logo and the text "Centers for Disease Control and Prevention" and "National Center for Health Statistics". The main content area is titled "Tabular List of Diseases: P04.14". A "Legend" section is visible with various icons. The main list of diseases is under the heading "CHAPTER 16: Certain conditions originating in the perinatal period (P00-P96)". The list includes categories like "Newborn affected by maternal factors and by other conditions originating in the perinatal period" and "Newborn affected by maternal use of drugs". The entry "P04.14 Newborn affected by maternal use of drugs" is highlighted. A pop-up window titled "Excludes2 : P04.14" is open, showing a list of conditions that are excluded from P04.14, including "CHAPTER 16: Certain conditions originating in the perinatal period (P00-P96)", "P04 Newborn affected by noxious substances transmitted via placenta or breast milk", and "P04.1 Newborn affected by other maternal medication".

ICD-10-CM

Centers for Disease Control and Prevention  
CDC 24/7: Saving Lives, Protecting People™

National Center for Health Statistics

Tabular List of Diseases: P04.14

Legend

CHAPTER 16: Certain conditions originating in the perinatal period (P00-P96)

Newborn affected by maternal factors and by other conditions originating in the perinatal period

P04 Newborn affected by noxious substances transmitted via placenta or breast milk

**P04.0 Newborn affected by maternal anesthesia and analgesia in pregnancy, labor and delivery (P04.0-)**

P04.1 Newborn affected by other maternal medication

**P04.11 Newborn affected by maternal use of general anesthetics**

**P04.12 Newborn affected by maternal use of sedatives, hypnotics, and tranquilizers**

**P04.13 Newborn affected by maternal use of antipsychotics**

**P04.14 Newborn affected by maternal use of drugs of addiction**

P04.15 Newborn affected by maternal use of antiepileptics

P04.16 Newborn affected by maternal use of antiemetics and anti-nausea drugs

P04.17 Newborn affected by maternal use of antidepressants

P04.18 Newborn affected by other maternal medication

P04.19 Newborn affected by maternal use of drugs of addiction

P04.1A Newborn affected by maternal use of drugs of addiction

P04.2 Newborn affected by maternal use of alcohol

P04.3 Newborn affected by maternal use of alcohol

Excludes2 : P04.14

- CHAPTER 16: Certain conditions originating in the perinatal period (P00-P96)
- congenital malformations, deformations and chromosomal abnormalities (Q00-Q99)
- endocrine, nutritional and metabolic diseases (E00-E88)
- injury, poisoning and certain other consequences of external causes (S00-T88)
- neoplasms (C00-D49)
- tetanus neonatorum (A33)

**P04 Newborn affected by noxious substances transmitted via placenta or breast milk**

- congenital malformations (Q00-Q99)
- encounter for observation of newborn for suspected diseases and conditions ruled out (Z05.-)
- neonatal jaundice from excessive hemolysis due to drugs or toxins transmitted from mother (P58.4)
- newborn in contact with and (suspected) exposures hazardous to health not transmitted via placenta or breast milk (Z77.-)

**P04.1 Newborn affected by other maternal medication**

- maternal anesthesia and analgesia in pregnancy, labor and delivery (P04.0)
- maternal use of drugs of addiction (P04.4-)

4  
 P. RON  
 K. A. R. O.  
 6.27.14  
 W/HARRIS

I'm afraid it's worse than  
 tendinitis, Mr. Tufnel.  
 It's elevendinitis.



ICD-10-CM Diagnosis codes for  
 tendinitis

M65.20	M65.2	M65.22	M65.23
M65.24	M65.25	M65.26	M65.27
M65.28	M65.29	M75.2	M75.3
M76.0	M76.1	M76.5	M76.6
M76.7	M76.82	Left Right	Unspecified